Skip to main content

Specialty Pharmacy

  • Report: FDA panel backs Amgen’s Humira biosimilar

  • FDA approves new Xolair indication
    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Xolair (omalizumab), Genentech  and Novartis, which work together to develop and co-promote the drug in the U.S., announced. 
     

  • Diplomat clinical services manager gets oncology pharmacist certification
    FLINT, Mich. — Diplomat Pharmacy announced this week that Kelly Procailo, the company’s clinical oncology manager inside its Clinical Services department has received certification as a Board Certified Oncology Pharmacist (BCOP) from the Board of Pharmacy Specialties. 
     

  • FDA approves 10th indication for Humira
    SILVER SPRING, Md. — The Food and Drug Administration has approved AbbVie’s Humira (adalimumab) to treat adults with non-infectious intermediate, posterior and panuveitas, the company announced Friday. Its new indication is the 10th for the drug in the U.S. for immune-meditated diseases.
     

  • FDA approves Gilead’s hepatitis C drug Epclusa
    SILVER SPRING, Md. — The Food and Drug Administration has approved Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the company announced earlier this week. Epclusa is a single tablet treatment for adults with genotype 1-6 chronic hepatitis and for patients with hepatitis C genotype 2 and 4 without the need for ribavirin. The drug for 12 weeks was approved for use in patients without cirrhosis or with compensated cirrhosis and in combination with ribavirin. 
     

  • CHPA case study explores teen abuse of dextromethorphan

    WASHINGTON -- The Consumer Healthcare Products Association has published a case study regarding efforts to curb teen abuse of over-the-counter cough medicine containing dextromethorphan. 

    The paper, “Dextromethorphan: a case study on addressing abuse of a safe and effective drug,” was published in Substance Abuse Treatment, Prevention, and Policy, an open access, peer-reviewed journal that encompasses research concerning substance abuse, with a focus on policy issues.

  • Senators, U.S. Rep introduce bill to shorten length of biologics exclusivity
    WASHINGTON — U.S. Rep. Jan Schakowsky and Sens. Sherrod Brown and John McCain on Thursday introduced a piece of legislation aimed at shortening the period of exclusivity for brand-name biologics products. The Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act would amend the Public Health Service act to change the exclusivity period from 12 years to seven years. 
     

  • Pharmasave pharmacists trained in medication therapy management

    VANCOUVER, B.C. -- Pharmasave announced that its pharmacists have been trained to be leaders in providing medication therapy management programs.

    This includes reviewing medications for appropriateness, identifying potential problems such as drug interactions, alternative therapies and contraindications and patient counselling on appropriate use. 

X
This ad will auto-close in 10 seconds